Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Collaborators: 4 (lowers risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: priordiseasesubjectto determinedl
  Phrases that lowered it: blood pressuremmhgand safetyefficacy andgastrointestinal
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 17.8% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 70.6% (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma NCT01462630 · started 2011 · scored riskier than 27% of active trials completed
• Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma NCT01532687 · started 2012 · scored riskier than 67% of active trials completed
• Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma NCT01107665 · started 2010 · scored riskier than 72% of active trials completed
• Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 NCT01566747 · started 2011 · scored riskier than 35% of active trials completed
• Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome NCT01436227 · started 2012 · scored riskier than 26% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.